Acadia Pharmaceuticals Inc. has announced upcoming presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders, scheduled for October 5-9 in Honolulu, Hawaii. The company will deliver a late-breaker oral platform presentation detailing the mechanism of action, preclinical efficacy, and safety evaluation of its investigational drug ACP-711, currently being developed for essential tremor. Additionally, Acadia will present two poster sessions: one outlining the design of a Phase 2, double-blind, placebo-controlled, multicenter study assessing the efficacy and safety of ACP-204 in adults with Lewy body dementia psychosis, and another reporting findings from a post-hoc analysis on the duration of illness and response to NUPLAZID® (pimavanserin) in patients with Parkinson's disease psychosis. The results and study designs will be presented during the congress and have not yet been publicly disclosed.